Surrey Heartlands

Joint Formulary & PAD

Golimumab - Rheumatoid arthritis

You are here : Home > Formulary Search > Golimumab - Rheumatoid arthritis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Subcutaneous injection (sc)
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
ICB
NICE
Restrictions / Comments :

Documentation

Guidelines (Local)
Rheumatoid Arthritis High cost immunomodulator drug pathway Apr-24.pdf
NICE Technology Appraisal
NICE TA375 - Biologics in Rheumatoid Arthritis - January 2016
NICE Technology Appraisal
NICE TA225 - Golimumab for rheumatoid arthritis after previous disease-modifying anti-rheumatic drugs - June 2011

PAD Profile

ChemicalSubstance :
Golimumab
Indication :
Rheumatoid arthritis
Group Name :
Keywords :
RA, Biologic, NICE, immunosuppressant, Cytokine modulator, TNF Alpha Inhibitor, DMARD, bDmard, Disease modulating, Rheumatology,
Brand Names Include :
Simponi
Important Information :
Severe disease only
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Rheumatoid arthritis
Supporting Documents :
3

Other Indications

Below are listed other indications that Golimumab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Rheumatoid arthritis.

Committee Recommendations (2)

03 Apr 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated rheumatoid arthritis pathway.

02 Dec 20 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Rheumatoid Arthritis High Cost DMARDs Drug Treatment Pathway. 

The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines.